ARTICLE | Deals
Sun takes shine to Checkpoint in $355M buyout: Deals Report
Plus: Jazz acquires Chimerix for 72% premium, and J&J does not exercise HexaBody Genmab option, Myokardia ends partnership with Fulcrum
March 10, 2025 9:48 PM UTC
Mumbai-based Sun Pharma is adding a newly approved PD-L1 inhibitor to its innovative products roster via the acquisition of Checkpoint for about $355 million up front.
Best known for its generic drugs, Sun Pharmaceutical Industries Ltd. (NSE:SUNPHARMA; BSE:524715) has built a small stable of biologics, sometimes via acquisitions. The latest is Unloxcyt cosibelimab, a PD-L1-blocking antibody developed by Checkpoint Therapeutics Inc. (NASDAQ:CKPT); FDA approved the mAb in December to treat cutaneous squamous cell carcinoma (cSCC)...